Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial

被引:37
作者
Deconinck, E [1 ]
Lamy, T
Foussard, C
Gaillard, F
Delwail, V
Colombat, P
Casassus, P
Lemevel, A
Brion, A
Milpied, N
机构
[1] CHU Besancon, Hop Jean Minjoz, Serv Hematol, F-25030 Besancon, France
[2] Ponchailloux Univ Hosp, Rennes, France
[3] Univ Hosp, Angers, France
[4] Hotel Dieu Univ Hosp, Nantes, France
[5] Univ Hosp, Poitiers, France
[6] Bretonneau Univ Hosp, Tours, France
[7] Avicenne Hosp, Bobigny, France
[8] Gauducheau Anticanc Ctr, Rennes, France
关键词
anaplastic; diffuse large-cell lymphoma; CD30; autologous stem cell transplantation; prognostic factor;
D O I
10.1046/j.1365-2141.2000.02098.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Autologous stem cell transplantation (ASCT) in the front line treatment of non-Hodgkin's lymphoma (NHL) remains controversial. Anaplastic large-cell lymphoma (ALCL) is known to have its own clinical and biological features. The outcome of ALCL patients treated with high-dose chemotherapy and ASCT as part of their first-line therapy was analysed in 202 intermediate or high-grade NHL patients in a prospective randomized trial. First-line chemotherapy comprised two alternating anthracycline-containing regimens. Responding patients were autografted after a BEAM (BCNU, cytarabine, etoposide and melphalan) regimen. Patients with bulky or residual masses were irradiated. Fifteen patients with ALCL were identified by morphological and immunological features (CD30 was expressed in 14 out of 15 patients, three patients expressed B-cell markers, five patients expressed T-cell markers and seven patients did not express cell markers). Anaplastic lymphoma kinase (ALK) expression was confirmed in seven cases. The median age was 39 years with a predominant male sex ratio (2.75). Thirteen patients were stage greater than or equal to III and six presented with two or more adverse prognostic factors. According to the international age-adjusted prognostic index, the expected complete remission (CR), event-free survival (EFS) and overall survival (OS) rates were 69%, 71% and 69%. Two deaths were observed (one due to interstitial pneumonitis, one due to pulmonary carcinoma). All patients entered CR, no relapse occurred and EFS and survival reached 87% with a follow-up of more than 5 years. These results differ significantly from those observed in the other 176 lymphoma patients: event-free survival was only 53 +/- 5% and OS reached 60 +/- 4% with a median follow-up of 56 months (P = 0.006). Intensified chemotherapy with autologous stem cell support appeared effective in the treatment of ALCL, offering patients the real chance of a cure.
引用
收藏
页码:736 / 742
页数:7
相关论文
共 35 条
[21]  
2-R
[22]   ANAPLASTIC LARGE-CELL LYMPHOMA (CD30+/KI-1+) - RESULTS OF A PROSPECTIVE CLINICOPATHOLOGICAL STUDY OF 69 CASES [J].
PILERI, S ;
BOCCHIA, M ;
BARONI, CD ;
MARTELLI, M ;
FALINI, B ;
SABATTINI, E ;
GHERLINZONI, F ;
AMADORI, S ;
POGGI, S ;
MAZZA, P ;
BURGIO, V ;
ZINZANI, PL ;
MELILLI, G ;
BENNI, M ;
SARAGONI, L ;
MARTELLI, MF ;
STEIN, H ;
MANDELLI, F ;
TURA, S .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (03) :513-523
[23]   SUCCESSFUL TREATMENT STRATEGY FOR KI-1 ANAPLASTIC LARGE-CELL LYMPHOMA OF CHILDHOOD - A PROSPECTIVE ANALYSIS OF 62 PATIENTS ENROLLED IN 3 CONSECUTIVE BERLIN-FRANKFURT-MUNSTER GROUP STUDIES [J].
REITER, A ;
SCHRAPPE, M ;
TIEMANN, M ;
PARWARESCH, R ;
ZIMMERMANN, M ;
YAKISAN, E ;
DOPFER, R ;
BUCSKY, P ;
MANN, G ;
GADNER, H ;
RIEHM, H .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (05) :899-908
[24]   LONG-TERM PROGNOSTIC IMPORTANCE OF PRIMARY KI-1 (CD30) ANTIGEN EXPRESSION AND ANAPLASTIC MORPHOLOGY IN ADULT PATIENTS WITH DIFFUSE LARGE-CELL LYMPHOMA [J].
ROMAGUERA, JE ;
MANNING, JT ;
TORNOS, CS ;
RODRIGUEZ, J ;
BROOKS, TE ;
PUGH, WC ;
ORDONEZ, NG ;
GOODACRE, AM ;
CABANILLAS, F .
ANNALS OF ONCOLOGY, 1994, 5 (04) :317-322
[25]  
ROSENBERG SA, 1982, CANCER, V49, P2112
[26]   Amplification of genomic DNA demonstrates the presence of the t(2;5)(p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis [J].
Sarris, AH ;
Luthra, R ;
Papadimitracopoulou, V ;
Waasdorp, M ;
Dimopoulos, MA ;
McBride, JA ;
Cabanillas, F ;
Duvic, M ;
Deisseroth, A ;
Morris, SW ;
Pugh, WC .
BLOOD, 1996, 88 (05) :1771-1779
[27]   DIAGNOSIS OF T(2-5)(P23-Q35)-ASSOCIATED KI-1 LYMPHOMA WITH IMMUNOHISTOCHEMISTRY [J].
SHIOTA, M ;
FUJIMOTO, J ;
TAKENAGA, M ;
SATOH, H ;
ICHINOHASAMA, R ;
ABE, M ;
NAKANO, M ;
YAMAMOTO, T ;
MORI, S .
BLOOD, 1994, 84 (11) :3648-3652
[28]   International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-hodgkin's lymphomas: Report of the jury [J].
Shipp, MA ;
Abeloff, MD ;
Antman, KH ;
Carroll, G ;
Hagenbeek, A ;
Loeffler, M ;
Montserrat, E ;
Radford, JA ;
Salles, G ;
Schmitz, N ;
Symann, M ;
Armitage, JO ;
Philip, T ;
Coiffier, B .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :423-429
[29]   A PREDICTIVE MODEL FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA [J].
SHIPP, MA ;
HARRINGTON, DP ;
ANDERSON, JR ;
ARMITAGE, JO ;
BONADONNA, G ;
BRITTINGER, G ;
CABANILLAS, F ;
CANELLOS, GP ;
COIFFIER, B ;
CONNORS, JM ;
COWAN, RA ;
CROWTHER, D ;
DAHLBERG, S ;
ENGELHARD, M ;
FISHER, RI ;
GISSELBRECHT, C ;
HORNING, SJ ;
LEPAGE, E ;
LISTER, TA ;
MEERWALDT, JH ;
MONTSERRAT, E ;
NISSEN, NI ;
OKEN, MM ;
PETERSON, BA ;
TONDINI, C ;
VELASQUEZ, WA ;
YEAP, BY .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :987-994
[30]   PRIMARY KI-1 ANAPLASTIC LARGE-CELL LYMPHOMA IN ADULTS - CLINICAL CHARACTERISTICS AND THERAPEUTIC OUTCOME [J].
SHULMAN, LN ;
FRISARD, B ;
ANTIN, JH ;
WHEELER, C ;
PINKUS, G ;
MAGAURAN, N ;
MAUCH, P ;
NOBLES, E ;
MASHAL, R ;
CANELLOS, G ;
TUNG, N ;
KADIN, M .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (05) :937-942